Odyssey Therapeutics, Inc. (ODTX) stock
ODTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026
$18.98−0.39 (-2.01%)
Close on Nov 18, 2026Market cap $912.15MP/E –Yield –
Odyssey Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$55.47M | – |
| Q1 FY2026 | Mar 31, 2026 | -$39.78M | – |
| Q2 FY2025 | Jun 30, 2025 | -$41.92M | – |
| Q1 FY2025 | Mar 31, 2025 | -$39.16M | – |
See a number that looks wrong?